Search Within

Elisa De Stanchina

Formats
  1. Journal Article (238)
  2. Meeting Abstract (103)
  3. Book Section (4)
  4. Research Letter (3)
  5. Book Whole (1)
  6. Correspondence (1)
  7. Review (1)
Groups
  1. GSK Faculty (281)
  2. Sloan Kettering Institute Postdocs (250)
  3. Department of Medicine (245)
  4. Solid Tumor Oncology Division (200)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (156)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (150)

More Groups

People
  1. Charles Rudin (70)
  2. Marissa Mattar (44)
  3. Marc Ladanyi (43)
  4. Neal Rosen (36)
  5. Inna Khodos (35)
  6. Romel Somwar (33)

More People

Years
  1. 2025 (15)
  2. 2024 (30)
  3. 2023 (23)
  4. 2022 (51)
  5. 2021 (43)
  6. 2020 (28)

More Years

Publications
  1. Cancer Research (52)
  2. Cancer Discovery (24)
  3. Clinical Cancer Research (19)
  4. Blood (16)
  5. Journal of Thoracic Oncology (16)
  6. Journal of Clinical Oncology (15)

More Publications

Publishers
  1. American Association for Cancer Research (111)
  2. Nature Publishing Group (42)
  3. Cell Press (36)
  4. Elsevier Inc. (28)
  5. American Society of Clinical Oncology (18)
  6. American Society of Hematology (16)

More Publishers

Results (351)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy
    Journal Article

    Oricchio, E.; Ciriello, G.; Jiang, M.; Boice, M. H.; Schatz, J. H.; Heguy, A.; Viale, A.; de Stanchina, E.; Teruya-Feldstein, J.; Bouska, A.; more...
    Journal of Experimental Medicine (2014)

    Fulltext@MSK | Save
  • Acquired resistance of EGFR-mutant lung Adenocarcinomas to Afatinib plus Cetuximab is associated with activation of mTORC1
    Journal Article

    Pirazzoli, V.; Nebhan, C.; Song, X.; Wurtz, A.; Walther, Z.; Cai, G.; Zhao, Z.; Jia, P.; de Stanchina, E.; Shapiro, E. M.; more...
    Cell Reports (2014)

    Fulltext@MSK | Save
  • Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs
    Journal Article

    Patwardhan, P. P.; Surriga, O.; Beckman, M. J.; de Stanchina, E.; DeMatteo, R. P.; Tap, W. D.; Schwartz, G. K.
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • The phosphoinositide 3-kinase a selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells
    Journal Article

    Musi, E.; Ambrosini, G.; de Stanchina, E.; Schwartz, G. K.
    Molecular Cancer Therapeutics (2014)

    Fulltext@MSK | Save
  • Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling
    Journal Article

    Will, M.; Qin, A. C. R.; Toy, W.; Yao, Z.; Rodrik-Outmezguine, V. ; Schneider, C.; Huang, X.; Monian, P.; Jiang, X.; de Stanchina, E.; more...
    Cancer Discovery (2014)

    Fulltext@MSK | Save
  • Prevention of minimal residual disease in Ph+ ALL
    Meeting Abstract

    Appelmann, I.; DeStanchina, E.; Carbonetti, G.; Chen, C.; Lowe, S. W.; Sherr, C. J.
    Blood (2013)

    Fulltext@MSK | Save
  • Epigenetic profiling of leukemia stem cells in a model of TET2/FLT3-mutant AML
    Meeting Abstract

    Shih, A. H.; Jiang, Y.; Shank, K.; Pandey, S.; Viale, A.; Sun, Y.; Socci, N.; Robertson, A.; de Stanchina, E.; Hricik, T.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Improved efficacy of combination of JAK2 and Hedgehog inhibitors in myelofibrosis
    Meeting Abstract

    Bhagwat, N.; Keller, M. D.; Rampal, R. K.; Shank, K.; de Stanchina, E.; Rose, K.; Amakye, D.; Levine, R. L.
    Blood (2013)

    Fulltext@MSK | Save
  • Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
    Meeting Abstract

    Rodrik-Outmezguine, V.; Yao, Z.; Berger, M.; De Stanchina, E.; Klinowska, T.; Barratt, D.; Baselga, J.; Rosen, N.
    Cancer Research (2013)

    Fulltext@MSK | Save
  • MLN0128, an investigational selective TORC1/2 kinase inhibitor, demonstrates potent antitumor activity in preclinical models of soft tissue sarcoma
    Meeting Abstract

    Patwardhan, P.; Deraje Vasudeva, S.; Tap, W. D.; de Stanchina, E.; Schwartz, G. K.
    Cancer Research (2013)

    Fulltext@MSK | Save